Testing zanzalintinib and cemiplimab for anaplastic thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, zanzalintinib and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer that has not spread to the brain or been treated with similar drugs. The study aims to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have anaplastic thyroid cancer that has not been treated with drugs like lenvatinib, sorafenib, or other similar targeted therapies.
- Your cancer is either too large to remove with surgery or has spread to other parts of your body.
- You are 18 or older and have a general health status that allows you to be up and about (ECOG 0-2).
- You have not received certain cancer treatments in the last 2-4 weeks, depending on the type.
- Your blood tests show adequate kidney, liver, and bone marrow function.
- You do not have untreated brain metastases or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests if a second course of targeted therapy (dabrafenib and trametinib) combined with chemotherapy can help people with a specific type of aggressive thyroid cancer (BRAF-positive anaplastic thyroid cancer) whose tumors stopped responding to initial targeted therapy.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.